These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9250455)

  • 1. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.
    Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA
    Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Vignati L; Anderson JH; Iversen PW
    Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group.
    Zinman B; Ross S; Campos RV; Strack T
    Diabetes Care; 1999 Apr; 22(4):603-8. PubMed ID: 10189539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections.
    Colombel A; Murat A; Krempf M; Kuchly-Anton B; Charbonnel B
    Diabet Med; 1999 Apr; 16(4):319-24. PubMed ID: 10220206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.
    Heller SR; Amiel SA; Mansell P
    Diabetes Care; 1999 Oct; 22(10):1607-11. PubMed ID: 10526722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
    Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
    Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A
    Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults : a real-life design.
    Stades AM; Hoekstra JB; van den Tweel I; Erkelens DW; Holleman F;
    Diabetes Care; 2002 Apr; 25(4):712-7. PubMed ID: 11919130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Pfützner A; Trautmann ME; Vignati L; DiMarchi R
    Diabetes; 1997 Feb; 46(2):265-70. PubMed ID: 9000704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
    Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
    Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).
    Rabasa-Lhoret R; Bourque J; Ducros F; Chiasson JL
    Diabetes Care; 2001 Apr; 24(4):625-30. PubMed ID: 11315820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.
    Jacobs MA; Keulen ET; Kanc K; Casteleijn S; Scheffer P; Devillé W; Heine RJ
    Diabetes Care; 1997 Aug; 20(8):1279-86. PubMed ID: 9250454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.